The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology
Open accessThe DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index.
Abstract
Lentiviral vectors have been developed and used in multiple gene and cell therapy applications. One of their main advantages over other vectors is the ability to integrate the genetic material into the genome of the host. However, this can also be a disadvantage as it may lead to insertional mutagenesis. To address this, non-integrating lentiviral vectors (NILVs) were developed. To generate NILVs, it is possible to introduce mutations in the viral enzyme integrase and/or mutations on the viral DNA recognised by integrase (the attachment sites). NILVs are able to stably express transgenes from episomal DNA in non-dividing cells or transiently if the target cells divide. It has been shown that these vectors are able to transduce multiple cell types and tissues. These characteristics make NILVs ideal vectors to use in vaccination and immunotherapies, among other applications. They also open future prospects for NILVs as tools for the delivery of CRISPR/Cas9 components, a recent revolutionary technology now widely used for gene editing and repair.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This also prevents the provirus formation while the vector DNA remains one of the primary episome types [10].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NILVs were optimised and modified to increase the transgene expression and to improvise the safety profile [10].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“NILVs can stably express transgenes from the episomal DNA in non-dividing cells or transiently if the target cells divide both in vitro and in vivo.”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 2×
“Lentiviral vectors have been derived from human immunodeficiency virus-1 (HIV-1) and developed by segregating the necessary genetic information to form an infectious particle in different plasmids, while removing the capability for replication [1].”
BackgroundMethodLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“In the last generation of these vectors, the regulatory protein Rev was removed from the packaging plasmid and coded from a fourth, distinct plasmid [3].”
BackgroundGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 2×
“In fact, there were several adverse events detected in clinical trials, later described, due to insertional mutagenesis [11,12].”
BackgroundMultiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977 · cited 1×
“Earlier vector generations used three plasmids for vector production: the packaging plasmid that codes for all necessary viral proteins for the particle formation and delivery of the transgene into target cells, the envelope plasmid coding for a glycoprotein that allows for the recognition of target cells, and the tra…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815 · cited 1×
“full-length transfer vector mRNA for incorporation into vector particles and do not rely on the viral protein Tat for transcription in the producer cells [7].”
BackgroundBurns, J. C., Friedmann, T., Driever, W., Burrascano, M., & Yee, J. K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8033 · Cited by 1,399 · cited 1×
“This envelope protein allows for the recognition of many target cells and also stabilises the vector particle [4], although other viral proteins have been used.”
BackgroundHowe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Malim, M. H., Hauber, J., Le, S.-Y., Maizel, J. V., & Cullen, B. R. (1989) · Nature · doi:10.1038/338254a0 · Cited by 1,280 · cited 11×
“Importantly, it is plausible to speculate that there may be designs to allow for an all-in-one design to provide the DNA template sequence from the same vector that also expresses the Cas9 protein and guide RNA necessary to enhance this cellular process.”
BackgroundInfluentialTransfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051 · cited 1×
“It was observed in this gene therapy clinical trial that the insertional activation of MDS1-EVI1, PRDM16 and SETBP1 increased the expansion of the gamma-retroviral vector-corrected cells in the treated individuals, potentiating the clinical benefit to patients [17].”
BackgroundZufferey, R., Donello, J. E., Trono, D., & Hope, T. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.4.2886-2892.1999 · Cited by 1,014 · cited 1×
“Additional modifications to the original transfer vector included the incorporation of a central polypurine tract (cPPT) that can increase the nuclear import of the viral DNA [8,9] and the incorporation of the post-translational regulatory element of the woodchuck hepatitis B virus (WPRE), shown to improve transgene e…”
BackgroundFollenzi, A., Ailles, L. E., Bakovic, S., Geuna, M., & Naldini, L. (2000) · Nature Genetics · doi:10.1038/76095 · Cited by 927
Lombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845 · cited 1×
“Other groups showed pre-clinical efficiency of ZFNs in relevant disease models, such as adenosine deaminase deficiency [101], X-SCID [102,103], and β-thalassemia [104] or meganucleases for Duchenne muscular dystrophy [105].”
BackgroundHIV-1 Genome Nuclear Import Is Mediated by a Central DNA Flap
Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L., & Charneau, P. (2000) · Cell · doi:10.1016/s0092-8674(00)80828-4 · Cited by 833 · cited 1×
“Additional modifications to the original transfer vector included the incorporation of a central polypurine tract (cPPT) that can increase the nuclear import of the viral DNA [8,9] and the incorporation of the post-translational regulatory element of the woodchuck hepatitis B virus (WPRE), shown to improve transgene e…”
BackgroundStein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716 · cited 1×
“However, later findings linked insertional activation of EVI1 to genomic instability, monosomy 7 and clonal progression toward myelodysplasia [18].”
BackgroundGaspar, H. B., Parsley, K. L., Howe, S., King, D., Gilmour, K. C., Sinclair, J., Brouns, G., Schmidt, M., Von Kalle, C., Barington, T., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17590-9 · Cited by 689 · cited 2×
“In fact, there were several adverse events detected in clinical trials, later described, due to insertional mutagenesis [11,12].”
BackgroundA role for LEDGF/p75 in targeting HIV DNA integration
Ciuffi, A., Llano, M., Poeschla, E., Hoffmann, C., Leipzig, J., Shinn, P., Ecker, J. R., & Bushman, F. (2005) · Nature Medicine · doi:10.1038/nm1329 · Cited by 658 · cited 2×
“The host-factor LEDGF/p75 is utilised by integrase to facilitate host-cell chromatin binding and targeting lentiviral DNA integration [26,27].”
BackgroundMethodGene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity
Braun, C. J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M., Modlich, U., Beier, R., Göhring, G., Steinemann, D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007280 · Cited by 562 · cited 1×
“However, 7 patients developed acute leukaemias associated with dominant clones that harboured vector integrations within or close to the LMO2, MDS1 and MN1 genes’ locus [16].”
BackgroundEngelman, A., & Craigie, R. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6361-6369.1992 · Cited by 519 · cited 2×
“The integrase viral enzyme is a proteolytic product of Pol and is composed of three domains: the N‐terminal domain, which contains a zinc‐binding motif [22] and binding of a zinc ion promotes multimerization of this protein [23]; the central domain that contains the catalytic core DD35E motif [24]; the C‐terminal doma…”
BackgroundLEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., & Engelborghs, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303594200 · Cited by 493 · cited 2×
“The host-factor LEDGF/p75 is utilised by integrase to facilitate host-cell chromatin binding and targeting lentiviral DNA integration [26,27].”
BackgroundMethodJohnson, M. S., McClure, M. A., Feng, D. F., Gray, J., & Doolittle, R. F. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.20.7648 · Cited by 480
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 2×
“Taking these observations together, Yanez-Munoz and colleagues tested lentiviral vectors that did not integrate their genome into host chromosomes and clearly demonstrated that these vectors maintained full capacity for transgene expression in target cells both in vitro and in vivo [37].”
BackgroundMultiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication
Engelman, A., Englund, G., Orenstein, J. M., Martin, M. A., & Craigie, R. (1995) · Journal of Virology · doi:10.1128/jvi.69.5.2729-2736.1995 · Cited by 445
Bushman, F. D., & Craigie, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1339 · Cited by 410 · cited 2×
“In the second catalytic step, named strand transfer, integrase mediates a concerted nucleophilic attack by the 3′-hydroxyl residues of the viral DNA on phosphodiester bridges located on either side of the major groove in the target DNA and a transesterification reaction where the viral 3′ ends are ligated to the 5′-O-…”
BackgroundZheng, R., Jenkins, T. M., & Craigie, R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13659 · Cited by 341 · cited 2×
“The integrase viral enzyme is a proteolytic product of Pol and is composed of three domains: the N‐terminal domain, which contains a zinc‐binding motif [22] and binding of a zinc ion promotes multimerization of this protein [23]; the central domain that contains the catalytic core DD35E motif [24]; the C‐terminal doma…”
BackgroundSite-specific integration and tailoring of cassette design for sustainable gene transfer
Lombardo, A., Cesana, D., Genovese, P., Di Stefano, B., Provasi, E., Colombo, D. F., Neri, M., Magnani, Z., Cantore, A., Lo Riso, P., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1674 · Cited by 331 · cited 1×
“They demonstrated 7–12% efficiency of homologous recombination [99], while the iSCeI meganuclease was successfully utilised in gene repair in other reports [39,100].”
MethodKatzman, M., Katz, R. A., Skalka, A. M., & Leis, J. (1989) · Journal of Virology · doi:10.1128/jvi.63.12.5319-5327.1989 · Cited by 311 · cited 2×
“Integration occurs in two catalytic steps: the viral integrase binds to the viral double-stranded DNA in the attachment (att) sites, which are two sets of conserved CA dinucleotides at the end of each of the viral LTRs, and removes the adjacent dinucleotide, in a process called 3′ processing [28].”
BackgroundMali, P., Ye, Z., Hommond, H. H., Yu, X., Lin, J., Chen, G., Zou, J., & Cheng, L. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0346 · Cited by 291 · cited 1×
“It was found that, although NILVs were able to generate iPS cells, the efficiency was ~50-fold lower compared to their integrating counterparts, and that regardless of the vector system used, all generated clones had an integrated copy of the SV40 large T antigen gene (most likely arising from illegitimate integration…”
ResultCell culture assays reveal the importance of retroviral vector design for insertional genotoxicity
Modlich, U., Bohne, J., Schmidt, M., von Kalle, C., Knöss, S., Schambach, A., & Baum, C. (2006) · Blood · doi:10.1182/blood-2005-08-024976 · Cited by 278 · cited 2×
“It was then evident that further vector development was necessary to reduce these adverse outcomes and the self-inactivating (SIN) vector design was shown to improve the biosafety profiles of these vectors [20,21].”
Shoemaker, C., Goff, S., Gilboa, E., Paskind, M., Mitra, S. W., & Baltimore, D. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3932 · Cited by 259 · cited 2×
“Additionally, there are other viral DNA circles produced by intramolecular integration [33].”
BackgroundPhilippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., & Serguera, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606197103 · Cited by 249
Emiliani, S., Mousnier, A., Busschots, K., Maroun, M., Van Maele, B., Tempé, D., Vandekerckhove, L., Moisant, F., Ben-Slama, L., Witvrouw, M., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501378200 · Cited by 242
Leavitt, A. D., Robles, G., Alesandro, N., & Varmus, H. E. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.721-728.1996 · Cited by 232 · cited 1×
“Mutation of any amino acid of the catalytic triad (in HIV-1, these are D64, D116 and E152 residues) results in a catalytic-dead enzyme, therefore increasing the amount of unintegrated vector DNA while reducing the amount of DNA molecules that stably integrate into the host chromosomes up to 1000 fold [38].”
BackgroundTransient Gene Expression by Nonintegrating Lentiviral Vectors
Nightingale, S. J., Hollis, R. P., Pepper, K. A., Petersen, D., Yu, X.-J., Yang, C., Bahner, I., & Kohn, D. B. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.008 · Cited by 192 · cited 1×
“These mutations can reduce integration up to 10000-fold [42].”
BackgroundStable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
Apolonia, L., Waddington, S. N., Fernandes, C., Ward, N. J., Bouma, G., Blundell, M. P., Thrasher, A. J., Collins, M. K., & Philpott, N. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300281 · Cited by 174 · cited 1×
“However, the combination of mutations in the viral DNA and in the viral integrase can reduce illegitimate or background integration but does not act synergistically to lower integration much further [40,43].”
BackgroundSelf-citationJu, G., & Skalka, A. M. (1980) · Cell · doi:10.1016/0092-8674(80)90348-7 · Cited by 168 · cited 6×
“Integration occurs in two catalytic steps: the viral integrase binds to the viral double‐stranded DNA in the attachment (att) sites, which are two sets of conserved CA dinucleotides at the end of each of the viral LTRs, and removes the adjacent dinucleotide, in a process called 3′ processing [28].”
BackgroundInfluentialOrtinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146 · cited 2×
“targeted γ-amino-butyric acid A receptor subunit a2 by knocking out the expression of this protein and demonstrated the feasibility of this system in vivo in neurons [109].”
BackgroundInsertional Gene Activation by Lentiviral and Gammaretroviral Vectors
Bokhoven, M., Stephen, S. L., Knight, S., Gevers, E. F., Robinson, I. C., Takeuchi, Y., & Collins, M. K. (2009) · Journal of Virology · doi:10.1128/jvi.01865-08 · Cited by 138 · cited 2×
“It was then evident that further vector development was necessary to reduce these adverse outcomes and the self-inactivating (SIN) vector design was shown to improve the biosafety profiles of these vectors [20,21].”
BackgroundNovel Integrase-Defective Lentiviral Episomal Vectors for Gene Transfer
Vargas, J., Gusella, G. L., Najfeld, V., Klotman, M. E., & Cara, A. (2004) · Human Gene Therapy · doi:10.1089/104303404322959515 · Cited by 133 · cited 1×
“This was accomplished by introducing the SV40 or EBV origins of replication in the NILV genome and the delivery of these vectors into cells expressing the SV40 large T antigen or the EBV nuclear antigen 1, respectively [59,60].”
MethodGutiérrez-Guerrero, A., Cosset, F., & Verhoeyen, E. (2020) · Viruses · doi:10.3390/v12091016 · Cited by 131 · cited 1×
“This process is called pseudotyping, and it is a topic covered in another review within this Special Issue [5].”
BackgroundEarly Transcription from Nonintegrated DNA in Human Immunodeficiency Virus Infection
Wu, Y., & Marsh, J. W. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10376-10382.2003 · Cited by 124
Petrillo, C., Thorne, L. G., Unali, G., Schiroli, G., Giordano, A. M. S., Piras, F., Cuccovillo, I., Petit, S. J., Ahsan, F., Noursadeghi, M., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.10.008 · Cited by 106 · cited 2×
“Although untested in the NILV format, the treatment of hematopoietic stem cells with Cyclosporine H augmented transduction of integrating lentiviral vectors by downmodulating IFITM3 [55], and, through a not yet identified mechanism, the use of PGE2 [56] or proteasome inhibitors [57,58] also increased transduction of l…”
BackgroundTargeted Genome Modifications Using Integrase-deficient Lentiviral Vectors
Cornu, T. I., & Cathomen, T. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300345 · Cited by 105 · cited 1×
“They demonstrated 7–12% efficiency of homologous recombination [99], while the iSCeI meganuclease was successfully utilised in gene repair in other reports [39,100].”
MethodHuman Immunodeficiency Virus Type 1 (HIV-1) Vpr Enhances Expression from Unintegrated HIV-1 DNA
Poon, B., & Chen, I. S. Y. (2003) · Journal of Virology · doi:10.1128/jvi.77.7.3962-3972.2003 · Cited by 105 · cited 2×
“Yet another approach has been the use of viral proteins known to alter and optimise the host cell for increased transgene delivery and expression, such as Vpr [36] and Vpx [50,51], or the alteration of the cell conditions via drug treatment.”
BackgroundRahim, A. A., Wong, A. M. S., Howe, S. J., Buckley, S. M. K., Acosta-Saltos, A. D., Elston, K. E., Ward, N. J., Philpott, N. J., Cooper, J. D., Anderson, P. N., et al. (2009) · Gene Therapy · doi:10.1038/gt.2008.186 · Cited by 101
Murine leukemia virus: detection of unintegrated double-stranded DNA forms of the provirus.
Gianni, A. M., Smotkin, D., & Weinberg, R. A. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.2.447 · Cited by 100 · cited 1×
“Interestingly, in addition to the integrated provirus, other extrachromosomal viral DNA species were identified early in retrovirus research [30,31].”
BackgroundKantor, B., Ma, H., Webster-Cyriaque, J., Monahan, P. E., & Kafri, T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905859106 · Cited by 98 · cited 2×
“Other approaches include the removal of cis-acting elements from the U3 region of the LTR [49] or adding other cis-elements to enhance transcription, such as the IS2 element, a synthetic scaffold attachment region combined with the chicken haemoglobin HS4 insulator [47].”
BackgroundMethodA Large U3 Deletion Causes Increased In Vivo Expression from a Nonintegrating Lentiviral Vector
Bayer, M., Kantor, B., Cockrell, A., Ma, H., Zeithaml, B., Li, X., McCown, T., & Kafri, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.199 · Cited by 94 · cited 12×
“Integration occurs in two catalytic steps: the viral integrase binds to the viral double‐stranded DNA in the attachment (att) sites, which are two sets of conserved CA dinucleotides at the end of each of the viral LTRs, and removes the adjacent dinucleotide, in a process called 3′ processing [28].”
MethodInfluentialVARMUS, H. E., Guntaka, R. V., Fan, W. J.-W., Heasley, S., & Bishop, J. M. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.10.3874 · Cited by 89 · cited 1×
“Interestingly, in addition to the integrated provirus, other extrachromosomal viral DNA species were identified early in retrovirus research [30,31].”
BackgroundWang, C. X., Sather, B. D., Wang, X., Adair, J., Khan, I., Singh, S., Lang, S., Adams, A., Curinga, G., Kiem, H.-P., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546218 · Cited by 88 · cited 1×
“Examples of the latter, although not specific for NILVs, include: target cell treatment with rapamycin, which enhances post-binding endocytic events via mammalian target of rapamycin (mTOR) inhibition [52]; treatment with caraphenol A, a cyclic resveratrol trimer that alters the levels of interferon-induced transmembr…”
BackgroundKarwacz, K., Mukherjee, S., Apolonia, L., Blundell, M. P., Bouma, G., Escors, D., Collins, M. K., & Thrasher, A. J. (2009) · Journal of Virology · doi:10.1128/jvi.02519-08 · Cited by 87 · cited 1×
“Several pre-clinical studies have shown the efficacy of NILVs in raising an immune response against HIV-1 [77,79–82], influenza virus [83–85], Zika virus [86], human papillomavirus [87], vaccinia virus [88], West Nile virus [89], human cytomegalovirus [90], Hepatitis B virus [75], and malaria [91].”
Self-citationSomaiah, N., Block, M. S., Kim, J. W., Shapiro, G. I., Do, K. T., Hwu, P., Eder, J. P., Jones, R. L., Lu, H., ter Meulen, J. H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1025 · Cited by 87
Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector
Negri, D. R., Michelini, Z., Baroncelli, S., Spada, M., Vendetti, S., Buffa, V., Bona, R., Leone, P., Klotman, M. E., & Cara, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300241 · Cited by 84
Defining nucleic acid-binding properties of avian retrovirus integrase by deletion analysis
Mumm, S. R., & Grandgenett, D. P. (1991) · Journal of Virology · doi:10.1128/jvi.65.3.1160-1167.1991 · Cited by 81 · cited 2×
“The integrase viral enzyme is a proteolytic product of Pol and is composed of three domains: the N‐terminal domain, which contains a zinc‐binding motif [22] and binding of a zinc ion promotes multimerization of this protein [23]; the central domain that contains the catalytic core DD35E motif [24]; the C‐terminal doma…”
BackgroundSantoni de Sio, F. R., Cascio, P., Zingale, A., Gasparini, M., & Naldini, L. (2006) · Blood · doi:10.1182/blood-2005-10-4047 · Cited by 75
Sleeping Beauty Transposition From Nonintegrating Lentivirus
Vink, C. A., Gaspar, H. B., Gabriel, R., Schmidt, M., McIvor, R. S., Thrasher, A. J., & Qasim, W. (2009) · Molecular Therapy · doi:10.1038/mt.2009.94 · Cited by 74 · cited 1×
“Ultimately, safer gene addition therapies in dividing cells could be achieved by the use of NILVs to deliver the transgene that can then be the substrate of other integrating systems that display a safer integration profile compared to HIV-1 integrase—for example, the sleeping beauty transposase [66] or the Flp recomb…”
BackgroundHeffner, G. C., Bonner, M., Christiansen, L., Pierciey, F. J., Campbell, D., Smurnyy, Y., Zhang, W., Hamel, A., Shaw, S., Lewis, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.025 · Cited by 72 · cited 1×
“Although untested in the NILV format, the treatment of hematopoietic stem cells with Cyclosporine H augmented transduction of integrating lentiviral vectors by downmodulating IFITM3 [55], and, through a not yet identified mechanism, the use of PGE2 [56] or proteasome inhibitors [57,58] also increased transduction of l…”
BackgroundProtective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based Vaccine
Coutant, F., Frenkiel, M.-P., Despres, P., & Charneau, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003973 · Cited by 70 · cited 1×
“Several pre-clinical studies have shown the efficacy of NILVs in raising an immune response against HIV-1 [77,79–82], influenza virus [83–85], Zika virus [86], human papillomavirus [87], vaccinia virus [88], West Nile virus [89], human cytomegalovirus [90], Hepatitis B virus [75], and malaria [91].”
Izmiryan, A., Ganier, C., Bovolenta, M., Schmitt, A., Mavilio, F., & Hovnanian, A. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.008 · Cited by 68
Jin, C., Fotaki, G., Ramachandran, M., Nilsson, B., Essand, M., & Yu, D. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505869 · Cited by 66
Joglekar, A. V., Hollis, R. P., Kuftinec, G., Senadheera, S., Chan, R., & Kohn, D. B. (2013) · Molecular Therapy · doi:10.1038/mt.2013.106 · Cited by 65 · cited 1×
“Other groups showed pre-clinical efficiency of ZFNs in relevant disease models, such as adenosine deaminase deficiency [101], X-SCID [102,103], and β-thalassemia [104] or meganucleases for Duchenne muscular dystrophy [105].”
BackgroundGene Correction of a Duchenne Muscular Dystrophy Mutation by Meganuclease-Enhanced Exon Knock-In
Popplewell, L., Koo, T., Leclerc, X., Duclert, A., Mamchaoui, K., Gouble, A., Mouly, V., Voit, T., Pâques, F., Cédrone, F., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.081 · Cited by 65 · cited 1×
“Other groups showed pre-clinical efficiency of ZFNs in relevant disease models, such as adenosine deaminase deficiency [101], X-SCID [102,103], and β-thalassemia [104] or meganucleases for Duchenne muscular dystrophy [105].”
BackgroundPollack, S. M., Lu, H., Gnjatic, S., Somaiah, N., O’Malley, R. B., Jones, R. L., Hsu, F. J., & ter Meulen, J. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000183 · Cited by 65 · cited 1×
“Importantly, the report shows sustained NY-ESO-1-specific CD4+ and CD8+ T cell responses that were sustained for up to two years after immunisation with the NILV [93].”
Backgroundde Sio, F. R. S., Gritti, A., Cascio, P., Neri, M., Sampaolesi, M., Galli, C., Luban, J., & Naldini, L. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0705 · Cited by 58
Pelascini, L. P. L., Janssen, J. M., & Gonçalves, M. A. F. V. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.069 · Cited by 57 · cited 1×
“Several approaches to increase expression could be explored, such as stronger promoter or enhancer elements, codon-optimisation techniques to improve translation of the desired transgenes, or the use of histone deacetylase inhibitors to activate transcription [48].”
BackgroundKantor, B., Bayer, M., Ma, H., Samulski, J., Li, C., McCown, T., & Kafri, T. (2011) · Molecular Therapy · doi:10.1038/mt.2010.277 · Cited by 56 · cited 1×
“This PPT-deleted vector reduced integration 10-fold and contributed additionally to a mutation in the viral IN to decrease integration a further ~3-fold [44].”
BackgroundGrasso, F., Negri, D. R. M., Mochi, S., Rossi, A., Cesolini, A., Giovannelli, A., Chiantore, M. V., Leone, P., Giorgi, C., & Cara, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.27676 · Cited by 48 · cited 1×
“Several pre-clinical studies have shown the efficacy of NILVs in raising an immune response against HIV-1 [77,79–82], influenza virus [83–85], Zika virus [86], human papillomavirus [87], vaccinia virus [88], West Nile virus [89], human cytomegalovirus [90], Hepatitis B virus [75], and malaria [91].”
Pollack, S. M. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1419068 · Cited by 47
Hu, B., Dai, B., & Wang, P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.012 · Cited by 45
Suwanmanee, T., Hu, G., Gui, T., Bartholomae, C. C., Kutschera, I., von Kalle, C., Schmidt, M., Monahan, P. E., & Kafri, T. (2014) · Molecular Therapy · doi:10.1038/mt.2013.188 · Cited by 44 · cited 1×
“Additionally, NILVs have also demonstrated efficacy in pre-clinical models, such as retinal degeneration [37], Parkinson’s disease [72], Haemophilia B [73], or traumatic brain injury [74].”
BackgroundGenomic insertion of lentiviral DNA circles directed by the yeast Flp recombinase
Moldt, B., Staunstrup, N. H., Jakobsen, M., Yáñez-Muñoz, R. J., & Mikkelsen, J. G. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-60 · Cited by 44 · cited 1×
“Ultimately, safer gene addition therapies in dividing cells could be achieved by the use of NILVs to deliver the transgene that can then be the substrate of other integrating systems that display a safer integration profile compared to HIV-1 integrase—for example, the sleeping beauty transposase [66] or the Flp recomb…”
BackgroundIntegrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens
Gallinaro, A., Borghi, M., Bona, R., Grasso, F., Calzoletti, L., Palladino, L., Cecchetti, S., Vescio, M. F., Macchia, D., Morante, V., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00171 · Cited by 44
Efficient gene targeting mediated by a lentiviral vector-associated meganuclease
Izmiryan, A., Basmaciogullari, S., Henry, A., Paques, F., & Danos, O. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr524 · Cited by 42 · cited 1×
“They demonstrated 7–12% efficiency of homologous recombination [99], while the iSCeI meganuclease was successfully utilised in gene repair in other reports [39,100].”
MethodEfficient gene expression from integration-deficient lentiviral vectors in the spinal cord
Peluffo, H., Foster, E., Ahmed, S. G., Lago, N., Hutson, T. H., Moon, L., Yip, P., Wanisch, K., Caraballo-Miralles, V, Olmos, G., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.78 · Cited by 40
Kymäläinen, H., Appelt, J. U., Giordano, F. A., Davies, A. F., Ogilvie, C. M., Ahmed, S., Laufs, S., Schmidt, M., Bode, J., Yáñez‐Muñoz, R. J., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.172 · Cited by 40 · cited 1×
“Alternatively, the use of a scaffold/matrix attachment region [61–64] or a transient induction of cell cycle arrest [65] also allows prolonged expression, even if the cells divide.”
BackgroundUM171 Enhances Lentiviral Gene Transfer and Recovery of Primitive Human Hematopoietic Cells
Ngom, M., Imren, S., Maetzig, T., Adair, J. E., Knapp, D. J. H. F., Chagraoui, J., Fares, I., Bordeleau, M.-È., Sauvageau, G., Leboulch, P., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.009 · Cited by 40 · cited 1×
“Examples of the latter, although not specific for NILVs, include: target cell treatment with rapamycin, which enhances post-binding endocytic events via mammalian target of rapamycin (mTOR) inhibition [52]; treatment with caraphenol A, a cyclic resveratrol trimer that alters the levels of interferon-induced transmembr…”
BackgroundSürün, D., Schwäble, J., Tomasovic, A., Ehling, R., Stein, S., Kurrle, N., von Melchner, H., & Schnütgen, F. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2017.11.001 · Cited by 39 · cited 1×
“Surun and colleagues have shown that a non-integrating lentiviral vector expressing CRISPR/Cas9 and a guide RNA targeting the cytochrome b-245 heavy chain (whose lack of expression results in chronic granulomatosis disease) can be used to correct this defect in hematopoietic cells [110].”
BackgroundSIVMAC Vpx improves the transduction of dendritic cells with nonintegrative HIV-1-derived vectors
Berger, G., Goujon, C., Darlix, J. L., & Cimarelli, A. (2008) · Gene Therapy · doi:10.1038/gt.2008.128 · Cited by 39 · cited 2×
“Yet another approach has been the use of viral proteins known to alter and optimise the host cell for increased transgene delivery and expression, such as Vpr [36] and Vpx [50,51], or the alteration of the cell conditions via drug treatment.”
BackgroundAlbershardt, T. C., Campbell, D. J., Parsons, A. J., Slough, M. M., ter Meulen, J., & Berglund, P. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.10 · Cited by 38
Hu, J., Schokrpur, S., Archang, M., Hermann, K., Sharrow, A. C., Khanna, P., Novak, J., Signoretti, S., Bhatt, R. S., Knudsen, B. S., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.009 · Cited by 37
Verghese, S. C., Goloviznina, N. A., Skinner, A. M., Lipps, H. J., & Kurre, P. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku082 · Cited by 37
Negri, D. R. M., Bona, R., Michelini, Z., Leone, P., Macchia, I., Klotman, M. E., Salvatore, M., & Cara, A. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.200 · Cited by 35
Ozog, S., Timberlake, N. D., Hermann, K. J., Garijo, O., Haworth, K. G., Shi, G., Glinkerman, C. M., Schefter, L. E., D'Souza, S. S., Simpson, E., et al. (2019) · Blood · doi:10.1182/blood.2019000040 · Cited by 33 · cited 1×
“Examples of the latter, although not specific for NILVs, include: target cell treatment with rapamycin, which enhances post-binding endocytic events via mammalian target of rapamycin (mTOR) inhibition [52]; treatment with caraphenol A, a cyclic resveratrol trimer that alters the levels of interferon-induced transmembr…”
BackgroundCoutant, F., Sanchez David, R. Y., Félix, T., Boulay, A., Caleechurn, L., Souque, P., Thouvenot, C., Bourgouin, C., Beignon, A.-S., & Charneau, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048644 · Cited by 32 · cited 1×
“Several pre-clinical studies have shown the efficacy of NILVs in raising an immune response against HIV-1 [77,79–82], influenza virus [83–85], Zika virus [86], human papillomavirus [87], vaccinia virus [88], West Nile virus [89], human cytomegalovirus [90], Hepatitis B virus [75], and malaria [91].”
Tareen, S. U., Kelley-Clarke, B., Nicolai, C. J., Cassiano, L. A., Nelson, L. T., Slough, M. M., Vin, C. D., Odegard, J. M., Sloan, D. D., Van Hoeven, N., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.278 · Cited by 32 · cited 1×
“NILVs have also been designed to specifically target professional antigen presenting cells, by using the Sindbis virus envelope glycoprotein that specifically targets DCs via the receptor DC-SIGN, which is expressed by these cells [92].”
BackgroundA Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus
Ku, M. W., Anna, F., Souque, P., Petres, S., Prot, M., Simon-Loriere, E., Charneau, P., & Bourgine, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.016 · Cited by 29 · cited 1×
“Several pre-clinical studies have shown the efficacy of NILVs in raising an immune response against HIV-1 [77,79–82], influenza virus [83–85], Zika virus [86], human papillomavirus [87], vaccinia virus [88], West Nile virus [89], human cytomegalovirus [90], Hepatitis B virus [75], and malaria [91].”
Blasi, M., Negri, D., LaBranche, C., Alam, S. M., Baker, E. J., Brunner, E. C., Gladden, M. A., Michelini, Z., Vandergrift, N. A., Wiehe, K. J., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0131-6 · Cited by 27
Yang, G., Si-Tayeb, K., Corbineau, S., Vernet, R., Gayon, R., Dianat, N., Martinet, C., Clay, D., Goulinet-Mainot, S., Tachdjian, G., et al. (2013) · BMC Biology · doi:10.1186/1741-7007-11-86 · Cited by 26 · cited 1×
“However, sorting and identification of cells by transient expression of easily assessed transgenes by NILVs was shown to be effective [107,108].”
BackgroundOdegard, J. M., Kelley-Clarke, B., Tareen, S. U., Campbell, D. J., Flynn, P. A., Nicolai, C. J., Slough, M. M., Vin, C. D., McGowan, P. J., Nelson, L. T., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000067 · Cited by 26 · cited 1×
“Several pre-clinical studies have shown the efficacy of NILVs in raising an immune response against HIV-1 [77,79–82], influenza virus [83–85], Zika virus [86], human papillomavirus [87], vaccinia virus [88], West Nile virus [89], human cytomegalovirus [90], Hepatitis B virus [75], and malaria [91].”
Negri, D. R. M., Michelini, Z., Baroncelli, S., Spada, M., Vendetti, S., Bona, R., Leone, P., Klotman, M. E., & Cara, A. (2010) · BioMed Research International · doi:10.1155/2010/534501 · Cited by 25
Lu‐Nguyen, N., Broadstock, M., Schliesser, M. G., Bartholomae, C. C., Kalle, C. V., Schmidt, M., & Yáñez‐Muñoz, R. J. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.003 · Cited by 25 · cited 1×
“Additionally, NILVs have also demonstrated efficacy in pre-clinical models, such as retinal degeneration [37], Parkinson’s disease [72], Haemophilia B [73], or traumatic brain injury [74].”
BackgroundTargeted gene modification in mouse ES cells using integrase‐defective lentiviral vectors
Okada, Y., Ueshin, Y., Hasuwa, H., Takumi, K., Okabe, M., & Ikawa, M. (2009) · genesis · doi:10.1002/dvg.20469 · Cited by 23 · cited 1×
“Here, NILVs have been used to deliver genetic material that can then be used as template for homologous recombination and thus gene editing of target cells [98].”
MethodSimian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines
Negri, D. R. M., Rossi, A., Blasi, M., Michelini, Z., Leone, P., Chiantore, M. V., Baroncelli, S., Perretta, G., Cimarelli, A., Klotman, M. E., et al. (2012) · Retrovirology · doi:10.1186/1742-4690-9-69 · Cited by 23 · cited 2×
“Yet another approach has been the use of viral proteins known to alter and optimise the host cell for increased transgene delivery and expression, such as Vpr [36] and Vpx [50,51], or the alteration of the cell conditions via drug treatment.”
BackgroundDeng, Y., Guan, J., Wen, B., Zhu, N., Chen, H., Song, J., Yang, Y., Wang, Y., & Tan, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062684 · Cited by 21 · cited 1×
“Several pre-clinical studies have shown the efficacy of NILVs in raising an immune response against HIV-1 [77,79–82], influenza virus [83–85], Zika virus [86], human papillomavirus [87], vaccinia virus [88], West Nile virus [89], human cytomegalovirus [90], Hepatitis B virus [75], and malaria [91].”
Daenthanasanmak, A., Salguero, G., Borchers, S., Figueiredo, C., Jacobs, R., Sundarasetty, B. S., Schneider, A., Schambach, A., Eiz‐Vesper, B., Blasczyk, R., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.063 · Cited by 21
Xu, Z., Chen, F., Zhang, L., Lu, J., Xu, P., Liu, G., Xie, X., Mu, W., Wang, Y., & Liu, D. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-0067-0 · Cited by 20
Wee, E. G., Ondondo, B., Berglund, P., Archer, J., McMichael, A. J., Baltimore, D., ter Meulen, J. H., & Hanke, T. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.12.004 · Cited by 20
Ahmed, S., Waddington, S. N., Boza-Moran, M.-G., & Yáñez‐Muñoz, R. J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.029 · Cited by 20
Fontana, J. M., Christos, P. J., Michelini, Z., Negri, D. R. M., Cara, A., & Salvatore, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097270 · Cited by 18
Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization
Hu, P., Bi, Y., Ma, H., Suwanmanee, T., Zeithaml, B., Fry, N. J., Kohn, D. B., & Kafri, T. (2018) · Gene Therapy · doi:10.1038/s41434-018-0039-2 · Cited by 18 · cited 1×
“The same laboratory has also reported the development of a stable NILV packaging cell line that may aid in the production of clinical-grade vectors, comprising the D64E IN mutant together with a conditional self-inactivating vector and a deleted PPT [45], as well as the development of a vector genome with the expressi…”
BackgroundHamilton, A. M., Foster, P. J., & Ronald, J. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.111 · Cited by 17 · cited 1×
“However, sorting and identification of cells by transient expression of easily assessed transgenes by NILVs was shown to be effective [107,108].”
BackgroundGallinaro, A., Borghi, M., Pirillo, M. F., Cecchetti, S., Bona, R., Canitano, A., Michelini, Z., Di Virgilio, A., Olvera, A., Brander, C., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.013 · Cited by 15
Hu, P., Li, Y., Sands, M. S., McCown, T. J., & Kafri, T. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.25 · Cited by 15 · cited 5×
“The LV305 vector has the mutation D64V in the viral integrase and is a dendritic cell-targeted vector that expresses the New York oesophageal squamous cell carcinoma-1 (NY-ESO-1) cancer testis antigen from a PPT-deleted vector genome.”
BackgroundInfluentialLin, B., Gao, A., Zhang, R., Ma, H., Shen, H., Hu, Q., Zhang, H., Zhao, M., Lan, X., & Liu, K. (2015) · Medicine · doi:10.1097/md.0000000000001301 · Cited by 12
Safe and neuroprotective vectors for long-term traumatic brain injury gene therapy
Blanco‐Ocampo, D., Cawen, F. A., Álamo-Pindado, L. A., Negro‐Demontel, M. L., & Peluffo, H. (2019) · Gene Therapy · doi:10.1038/s41434-019-0073-8 · Cited by 12 · cited 1×
“Additionally, NILVs have also demonstrated efficacy in pre-clinical models, such as retinal degeneration [37], Parkinson’s disease [72], Haemophilia B [73], or traumatic brain injury [74].”
BackgroundShaw, A., Joseph, G. L., Jasti, A. C., Sastry, L., Witting, S. R., & Cornetta, K. G. (2016) · Gene Therapy · doi:10.1038/gt.2016.69 · Cited by 11 · cited 1×
“However, the combination of mutations in the viral DNA and in the viral integrase can reduce illegitimate or background integration but does not act synergistically to lower integration much further [40,43].”
BackgroundEpisomal lentiviral vectors confer erythropoietin expression in dividing cells
Chen, F., Qi, X., Zhang, R., Wu, Z., Yan, C., Li, J., Liu, Q., & Qi, J. (2017) · Plasmid · doi:10.1016/j.plasmid.2017.02.001 · Cited by 9
Shariati, L., Modarressi, M. H., Tabatabaiefar, M. A., Kouhpayeh, S., Hejazi, Z., Shahbazi, M., Sabzehei, F., Salehi, M., & Khanahmad, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28130 · Cited by 8
Molecular Evidence of Genome Editing in a Mouse Model of Immunodeficiency
Abdul-Razak, H. H., Rocca, C. J., Howe, S. J., Alonso-Ferrero, M. E., Wang, J., Gabriel, R., Bartholomae, C. C., Gan, V. C. H., Garin, M. I., Roberts, A. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26439-9 · Cited by 7 · cited 1×
“Other groups showed pre-clinical efficiency of ZFNs in relevant disease models, such as adenosine deaminase deficiency [101], X-SCID [102,103], and β-thalassemia [104] or meganucleases for Duchenne muscular dystrophy [105].”
BackgroundFlynn, R. P., Zacharias, J., Zhou, X., Cannon, M. L., & Philpott, N. J. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1601 · Cited by 4 · cited 1×
“This was accomplished by introducing the SV40 or EBV origins of replication in the NILV genome and the delivery of these vectors into cells expressing the SV40 large T antigen or the EBV nuclear antigen 1, respectively [59,60].”
Method
Cited by
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
“…(Ads) (Barouch and Picker, 2014; Ertl, 2016), cytomegaloviruses (Barouch and Picker, 2014), adeno‐associated viruses (AAV) (Andari and Grimm, 2020), poxviruses (Conrad and Liu, 2019), herpesviruses (Artusi et al., 2018), and retroviruses (Chen et al., 2018b; Luis, 2020; Stephenson et al., 2016).”
Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges
Mengstie, M. A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.895713 · Cited by 168
“Hence, the transient expression nature of NILVs in dividing cells, combined with their low immunogenicity makes them the most promising vector candidates to be used in clinical applications (Luis, 2020).”
BackgroundChitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines
Gong, X., Gao, Y., Shu, J., Zhang, C., & Zhao, K. (2022) · Vaccines · doi:10.3390/vaccines10111906 · Cited by 155
Approved and marketed nanoparticles for disease targeting and applications in COVID-19
Abdellatif, A. A. H., & Alsowinea, A. F. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0115 · Cited by 115
Bouazzaoui, A., Abdellatif, A. A. H., Al-Allaf, F. A., Bogari, N. M., Al-Dehlawi, S., & Qari, S. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020140 · Cited by 98
“The development of non-integrating lentiviral vector (NILVs) [58], which have the capacity to express transgenes transiently in dividing cells or episomes in non-dividing cells and can also be introduced into different cell types, has been a further interesting advancement in the use of lentiviral vectors.”
Background
Metadata
- Authors
- Apolonia, L.
- Affiliations
- King's College London (GB)
- Corresponding author
- Apolonia, Luis
- ORCID
- Apolonia, Luis
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2020-09-29
- Volume
- 12
- Issue
- 10
- Pages
- 1103
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC7600637
- OpenAlex
- W3089800965
- Semantic Scholar
- 324fbc09f8fa809d5a516e0740b3caede616fe8f
- Cited by
- 58
- References
- 113
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 13 · 2023: 9 · 2022: 7 · 2021: 13 · 2020: 1
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- lentiviral vectors, integrase mutations, insertional mutagenesis, episomal DNA, transgene expression, gene therapy, cell therapy, vaccination, immunotherapy, CRISPR/Cas9 delivery, genome editing
- MeSH terms
- DNA, Viral, Genetic Vectors, Immunotherapy, Plasmids, Genetic Therapy, Gene Expression, Lentivirus, Mutagenesis, Transgenes, Integrases, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.